Harvard Medical School has named Mark Namchuk, PhD, a former pharmaceutical R&D executive with a background in immunology and bioorganic chemistry, as executive director of therapeutics translation. Namchuk, who joins Harvard Medical School from Alkermes, will assume his role on Jan. 2.
Zirui Song discusses the pros and cons of concierge medicine
More efficient and authentic cell creation enables immune studies, drug development
Using this method, scientists discovered key protein and gene activity changes in aging and in a rare disease called progeria.
Gene-editing technologies developed by Harvard’s David Liu demonstrate game-changing potential in two recent cases.
Nicole Maestas on how cuts threaten quality, sustainability of care
Deep-learning algorithm analyzes snapshots for information that could help oncologists tailor treatment intensity.
Julia Merkenschlager explores how secrets of natural immunity can improve vaccines, treatment
Study solves riddle of how mutations in Integrator complex relate to neurodegeneration, cancer
AI model EVE-Vax provides valuable clues about how a virus may evolve
